Arcutis Biotherapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Arcutis Biotherapeutics Inc 's ROA in the third quarter of 2026?
Arcutis Biotherapeutics Inc achieved a return on average assets (ROA) of 11.64 % in its third quarter of 2026, this is above ARQT's average return on assets of -26.32%.
Arcutis Biotherapeutics Inc assets over the 12 months ending in its third quarter of 2026 are valued at $483 million

ROA decreased relative to the period ending Jun 30 2026, due to the decline in net income.

However, within the Healthcare sector 66 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 1376, from total ROA ranking in the second quarter of 2026 at 1533.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	46.2 %	39.93 %	33.53 %	23.92 %	-16.05 %
Y / Y Net Income Change	-40.93 %	-	-	-90.72 %	-
Net Income (TTM) in million	56	62	16	16	186
Return On Assets (TTM)	11.64 %	14.14 %	4.03 %	4.29 %	52.39 %
ARQT's Total Ranking	# 1376	# 1533	# 74	# 186	# 2615
Total Assets (TTM) in million	537	503	460	433	367
Seq. Total Assets Change	6.61 %	9.37 %	6.24 %	18.02 %	2.04 %
Seq. Net Income Change	-70.81 %	-	-	16.74 %	-

ARQT's 5 Years Annual ROA >> Back to ARQT Management Effectiveness >> Compare ARQT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 29
Sector	# 67
Overall	# 379

Return On Assets Statistics
High	Average	Low
52.57 %	-26.32 %	-79.91 %
(Sep 30 2025)		(Mar 31 2023)

Financial Statements
Arcutis Biotherapeutics Inc 's Assets	$ 537 million	ARQT's Balance sheet
Arcutis Biotherapeutics Inc 's Income	$ 9 million	Quarterly ARQT's Income Statement
ARQT's Income by Division		See ARQT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	24.16 %	2.23 %	-23.93 %	9.94 %	36.84 %
Total Assets in million	433	349	341	449	408
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-1	-1	-3	-311	-206
Annual Return On Assets	-0.27 %	-0.19 %	-0.91 %	-69.41 %	-50.56 %

ARQT's 5 Years Annual ROA >> Back to ARQT Management Effectiveness >> Compare ARQT ROA to its Competitors

More Return On Assets Ratios
ARQT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ARQT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ARQT's Competitors
Subscribers only: Roa for Arcutis Biotherapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ARQT's Customers

You may also want to know
ARQT's Roi	ARQT's Inventory Turnover Ratio	ARQT's Growth Rates	ARQT's Dividend Comparisons
	ARQT's Profitability Ratios	ARQT's Asset Turnover Ratio	ARQT's Dividend Growth
ARQT's Roe	ARQT's Valuation Ratios	ARQT's Financial Strength Ratios	ARQT's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Protalix Biotherapeutics inc	19.89 %
Electromed Inc	19.73 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Alpha Pro Tech Ltd	12.46 %
Tenet Healthcare Corp	12.39 %
Hca Healthcare Inc	11.73 %
Carlisle Companies Incorporated	11.72 %
Regeneron Pharmaceuticals Inc	11.50 %

Date modified: 2026-11-07T13:24:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.